# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- Reuters
Patients in MagnetisMM-3 demonstrated a median overall survival (OS) of 24.6 months, with median progression-free survival (P...
Pfizer Inc. reported that its Phase 3 CIFFREO study on Duchenne muscular dystrophy (DMD) gene therapy did not meet its primary ...
Moderna has submitted an FDA application for its 2024-2025 Spikevax formula, targeting the prevalent SARS-CoV-2 variant JN.1.
- Reuters